Statements (30)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:drug
|
gptkbp:approvalYear |
2010
|
gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
gptkbp:ATCCode |
gptkb:M04AX07
|
gptkbp:CASNumber |
gptkb:76801-97-1
|
gptkbp:contraindication |
gptkb:G6PD_deficiency
|
gptkbp:effect |
lowers serum uric acid
|
gptkbp:form |
solution for infusion
|
gptkbp:genericName |
gptkb:pegloticase
|
gptkbp:halfLife |
10-12 days
|
https://www.w3.org/2000/01/rdf-schema#label |
Krystexxa
|
gptkbp:indication |
treatment of chronic gout
|
gptkbp:KEGGID |
D08913
|
gptkbp:legalStatus |
prescription only
|
gptkbp:manufacturer |
gptkb:Horizon_Therapeutics
|
gptkbp:mechanismOfAction |
uricase enzyme
|
gptkbp:MedlinePlusID |
a611009
|
gptkbp:pregnancyCategory |
C (US)
|
gptkbp:PubChem_CID |
gptkb:DB05509
none |
gptkbp:routeOfAdministration |
intravenous
|
gptkbp:RxNorm |
1114972
|
gptkbp:sideEffect |
anaphylaxis
infusion reaction gout flare |
gptkbp:target |
uric acid
|
gptkbp:UNII |
QX9K0X4Q8P
|
gptkbp:bfsParent |
gptkb:Horizon_Therapeutics
|
gptkbp:bfsLayer |
7
|